1. Visible-Light-Controlled Histone Deacetylase Inhibitors for Targeted Cancer Therapy
- Author
-
Amadeu Llebaria, Laia Josa-Culleré, European Commission, and Ministerio de Ciencia e Innovación (España)
- Subjects
Histone Deacetylase Inhibitors ,Drug Discovery ,Cancer Therapy ,Chemotherapy ,Molecular Medicine - Abstract
The lack of selectivity of anticancer drugs limits current chemotherapy. Light-activatable drugs, whose activity can be precisely controlled with external light, could provide a more localized action of the drugs in the tumor, thus decreasing side effects and increasing efficacy. Herein, we introduce a series of photoswitchable azobenzene histone deacetylase inhibitors (HDACis) whose activity can be controlled by external visible light. Initial HDACis isomerized under ultraviolet light and were up to >50-fold more active under illumination than in the dark in enzyme assays. These were then optimized toward compounds responding to more permeable and less harmful green light by introducing o-halogen atoms into the azobenzene. Selected compounds decreased cell viability only under illumination in four different cancer cell lines. Overall, we present photoswitchable HDACis with optimized activation wavelengths, which inhibit enzyme activity and cell viability only upon illumination with visible light, contributing to the still limited toolbox of photoswitchable anticancer drugs., L.J.-C. has received funding from the European Union’s Horizon2020 research and innovation programme under Marie Sklodowska-Curie Grant Agreement 841089. A.L. received funding from Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación 10.13039/501100011033 and ERDF A way of making Europe (Projects I+D+i CTQ2017-89222-R and PID2020-120499RB-I00), and the Catalan government (2017 SGR 1604). The authors thank Dr. Lourdes Muñoz from SimChem (IQAC-CSIC) for analytical and instrumental support. The authors thank Dr. Wiktor Szymanski (University of Groningen, Groningen, The Netherlands) for helpful discussions.
- Published
- 2023
- Full Text
- View/download PDF